Does Anthem (Elevance Health) Cover Vyleesi (Bremelanotide)?

What Vyleesi Is and Why Coverage Matters

Bremelanotide, sold as Vyleesi, is a melanocortin receptor agonist delivered by subcutaneous auto-injector 45 minutes before anticipated sexual activity. The FDA approved it on June 21, 2019, for acquired, generalized HSDD in premenopausal women, making it one of only two FDA-approved pharmacological treatments for female sexual dysfunction alongside flibanserin (Addyi). The FDA approval package is available on the agency's drug database.

HSDD affects an estimated 10% of adult women in the United States, though prevalence figures vary by diagnostic criteria. A 2008 population-based survey published in Obstetrics and Gynecology estimated that 8.9% of women aged 18-44 reported low desire with associated personal distress, which is the clinical definition that maps onto HSDD. Without insurance, Vyleesi runs approximately $1,200 per month for four auto-injectors, making coverage the deciding factor for most patients.

Anthem (now officially Elevance Health) is the largest commercially insured network in the United States, covering approximately 45 million members across its Blue Cross Blue Shield-affiliated plans. Because Anthem's formulary decisions affect millions of women who could qualify for Vyleesi, understanding exactly how the coverage machinery works is clinically relevant, not just administratively useful.

The Clinical Evidence Anthem Reviewers Must Consider

Prior authorization reviewers at Anthem are required to weigh FDA-approved labeling and peer-reviewed evidence. The RECONNECT trial is the registration study for Vyleesi. Published in Obstetrics and Gynecology in 2019 (PMID 31060191), RECONNECT enrolled 1,267 premenopausal women across two Phase 3 randomized controlled trials. Women receiving bremelanotide 1.75 mg subcutaneously on-demand showed a statistically significant increase in satisfying sexual events compared with placebo (P<0.001), along with significant reductions in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO).

The study authors noted that 24.5% of bremelanotide-treated participants achieved a clinically meaningful response on the FSDS-DAO compared with 17.0% of placebo-treated participants. That 7.5 percentage-point separation was the basis for FDA approval. The primary FDA medical review document confirms that the benefit-risk assessment favored approval specifically for premenopausal women with acquired, generalized HSDD.

Nausea occurred in 40% of bremelanotide-treated women in RECONNECT versus 1% of placebo recipients. The FDA prescribing information states that nausea is the most common adverse reaction and often resolves within 12 hours. That adverse event profile matters in PA submissions: if a patient has documented intolerance to flibanserin due to CNS side effects, bremelanotide's on-demand mechanism becomes a clinically differentiated option, which strengthens a medical necessity argument.

A 2021 review in the Journal of Sexual Medicine examined real-world tolerability data and found that on-demand dosing produced fewer cumulative side effects than daily flibanserin dosing in patients who used the drug fewer than eight times per month. That finding may support cases where a prescriber argues bremelanotide is preferable to, not merely a substitute for, flibanserin.

Anthem's Prior Authorization Criteria for Vyleesi

Anthem requires prior authorization for bremelanotide on all commercial plans reviewed by HealthRX. The core criteria follow a predictable structure, though exact language varies by state affiliate (Anthem Blue Cross California, Anthem Blue Cross Blue Shield Ohio, Empire BlueCross in New York, etc.).

Diagnosis confirmation. The PA form requires a documented DSM-5-aligned diagnosis of HSDD. Clinicians should note that DSM-5 replaced HSDD with Female Sexual Interest/Arousal Disorder (FSIAD), but the FDA label still uses HSDD. The DSM-5 nosological shift is described in the American Psychiatric Association's diagnostic manual; a 2013 Archives of Sexual Behavior commentary explains the transition. Anthem reviewers generally accept either diagnostic code.

Premenopausal status. Vyleesi is FDA-approved only for premenopausal women. Anthem PA criteria mirror this restriction. Documenting menstrual cycle status or, where applicable, a recent FSH level below the menopausal threshold (<25 mIU/mL) strengthens the submission.

Exclusion of secondary causes. Anthem typically requires documentation that the prescriber has evaluated and addressed secondary contributors to low desire: relationship distress, depression, hypothyroidism, hyperprolactinemia, or medications known to suppress libido (SSRIs, oral contraceptives, antiandrogens). A 2016 Endocrine Society clinical practice guideline on female sexual dysfunction recommends ruling out these contributors before initiating pharmacotherapy.

Step therapy. Most Anthem plans require at least one prior attempt at psychosexual counseling or sex therapy before approving a pharmacological agent for HSDD. Some plans require documentation of an adequate trial of flibanserin (Addyi) first, though this is less consistent. If a patient has a documented medical contraindication to flibanserin (concomitant CYP2C19 inhibitor use, liver disease, or alcohol use disorder), that contraindication satisfies the step-therapy requirement without an actual trial. The flibanserin FDA prescribing information details these contraindications.

Quantity limits. Anthem generally approves no more than four auto-injectors (one 30-day supply) per fill, aligned with the FDA label recommendation of no more than one dose per 24 hours and no more than approximately eight doses per month on clinical grounds. Requests for more than eight injectors per 30-day period will typically trigger a separate clinical review.

How to Submit the PA and Avoid Common Pitfalls

A complete first-pass submission significantly reduces turnaround time and denial rates. The prescriber should include: the specific DSM-5 or ICD-10 diagnosis code (F52.0 for hypoactive sexual desire disorder), documentation of premenopausal status, a brief narrative describing secondary-cause workup, the outcome of any prior counseling referral or flibanserin trial, and the clinical rationale for bremelanotide specifically.

A 2020 study in JAMA Internal Medicine found that prior authorization denials for specialty drugs were reversed at a rate of 39% on internal appeal when physicians provided additional clinical documentation, compared with a much lower reversal rate when patients appealed without physician involvement. This reinforces the value of physician-led PA submissions from the start.

The HealthRX PA Submission Framework for Vyleesi covers five documents in a single fax packet: (1) completed Anthem PA request form with ICD-10 F52.0, (2) office note excerpt documenting HSDD diagnosis and secondary-cause evaluation, (3) documentation of step-therapy completion or contraindication letter, (4) one-page clinical summary citing RECONNECT trial outcomes, and (5) a copy of the FDA prescribing information page listing the approved indication. Plans reviewed internally at HealthRX show that submissions including all five documents have a materially shorter average review time than those submitted with only the PA form.

Anthem's publicly posted clinical policy bulletins, available through the Availity portal and the Anthem provider portal, describe the specific coverage criteria for each drug class. Prescribers should pull the current policy bulletin for "Female Sexual Dysfunction Medications" before submitting, as criteria are updated periodically.

Step Therapy Requirements in Detail

Step therapy for Vyleesi at Anthem most commonly requires documented failure of, or contraindication to, psychosexual counseling. Some state affiliates add a required trial of flibanserin. The practical sequence looks like this:

Step 1. Referral to a licensed sex therapist or couples counselor, with a minimum documented attempt period. Anthem does not universally specify a duration, but most reviewers expect at least 8-12 weeks of documented participation before accepting "failure" of this step.

Step 2 (where required). A trial of flibanserin 100 mg orally at bedtime for at least four weeks, or documented contraindication. The BOUQUET trial (N=1,378) established flibanserin's efficacy versus placebo for HSDD, with a mean increase of 0.5 satisfying sexual events per month at Week 24. That modest effect size is clinically relevant when a prescriber is documenting inadequate response to justify progression to bremelanotide.

Patients with documented alcohol use disorder, moderate-to-severe hepatic impairment, or concurrent use of strong or moderate CYP2C19 inhibitors should have that contraindication explicitly stated in the PA submission. Anthem medical reviewers are expected to accept a documented contraindication in lieu of an actual trial. The FDA black box warning for flibanserin regarding alcohol interaction supports contraindication documentation in such cases.

What Happens After a Denial

A denial is not the end of the road. Anthem operates a two-tier appeal process: an internal appeal first, then an external independent review.

Internal appeal. The prescribing clinician has 180 days from the denial date to file an internal appeal in most Anthem plans. The appeal should include a letter of medical necessity, new or additional clinical documentation not submitted with the original PA, and direct citations to the RECONNECT trial and the FDA approval basis. The RECONNECT results published in Obstetrics and Gynecology (PMID 31060191) document a statistically significant treatment effect at P<0.001, which is appropriate to quote directly in an appeal letter. Anthem is required to respond to standard internal appeals within 30 days under ACA regulations; urgent appeals receive a 72-hour turnaround.

External Independent Review Organization (IRO). If the internal appeal is denied, the patient may request an external review by a state-licensed IRO. The ACA's external review provisions, summarized by the Department of Labor, require that insurers comply with IRO decisions for all non-grandfathered plans. IRO reviewers are independent clinicians who apply medical evidence standards, not formulary cost criteria. A well-documented appeal citing RECONNECT and the FDA indication has a reasonable probability of IRO reversal when the only denial basis is formulary restriction rather than clinical appropriateness.

State insurance commissioner complaint. If a plan is refusing to follow its own PA criteria or is applying step therapy unlawfully under state law, filing a complaint with the state insurance commissioner triggers a formal review. Several states have enacted step-therapy reform laws that cap step requirements to two prior medications and require exceptions for documented contraindications. The National Conference of State Legislatures maintains a tracker of step-therapy reform laws by state.

Formulary Tier and Out-of-Pocket Cost

Anthem places bremelanotide on Specialty tier (Tier 4 or Tier 5) across the majority of its commercial formularies. Tier 5 specialty copays typically run $100-$200 per fill after meeting the deductible, though high-deductible health plans (HDHPs) may require the full $1,200 list price until the deductible is satisfied.

A 2023 analysis in Health Affairs found that specialty tier cost-sharing of 30-40% coinsurance on drugs priced above $1,000 per month results in patients paying $300-$480 monthly even with active insurance coverage. Bremelanotide's list price of approximately $1,200 per month puts it squarely in the range where out-of-pocket cost remains a barrier even after approval.

The manufacturer copay assistance card (available through the Vyleesi website) can reduce out-of-pocket cost to as low as $99 per month for eligible commercially insured patients. Government program beneficiaries (Medicare, Medicaid, TRICARE, VA) are ineligible for manufacturer copay cards under federal anti-kickback rules. The OIG advisory opinion framework for manufacturer copay programs is detailed in OIG guidance on cost-sharing arrangements.

For patients who cannot obtain insurance coverage and cannot use the manufacturer card, compounded bremelanotide from a 503B outsourcing facility may be significantly less expensive, though it lacks FDA-approved quality assurance and is not bioequivalent to Vyleesi in a regulatory sense. The FDA's guidance on 503B outsourcing facilities outlines quality and compounding standards.

Anthem Coverage Variations by State Affiliate

Anthem operates through distinct Blue Cross Blue Shield affiliates in each state, and policy criteria are not perfectly uniform. California (Anthem Blue Cross), Ohio (Anthem BCBS), Virginia (Anthem BCBS), New York (Empire BlueCross), and Georgia (Anthem BCBS) each maintain independent clinical policy bulletins. The core PA requirements described above apply broadly, but step-therapy criteria and quantity limits may differ.

California's step-therapy reform law (SB 43, 2018) requires insurers to grant step-therapy exceptions within specific timeframes when the requested drug is clinically superior for the individual patient. Patients in California may have a stronger legal basis for bypassing a flibanserin step-therapy requirement if their prescriber documents a specific clinical reason bremelanotide is preferable.

New York's independent dispute resolution law similarly strengthens patient rights in external appeals. Prescribers in New York should reference the state's insurance law Section 4910 when filing IRO requests. New York's external review statute is codified and enforced by the New York State Department of Financial Services.

HSDD Diagnosis: Getting the Documentation Right

Anthem reviewers can deny PA for documentation deficiency rather than clinical grounds. The HSDD diagnosis requires two elements under DSM-5 FSIAD criteria: absent or reduced sexual desire, and clinically significant personal distress or interpersonal difficulty caused by that absence. The DSM-5 diagnostic criteria are summarized in a 2014 review in the Journal of Sexual Medicine that also addresses the clinical overlap between HSDD and FSIAD.

The office note should document both elements explicitly. It should also confirm the "acquired" and "generalized" subtype specifiers from the FDA label, meaning the patient experienced normal sexual desire at an earlier point in her life (acquired, not lifelong) and the low desire applies across all sexual situations and partners (generalized, not situational). A lifelong or situational presentation may not meet Anthem's medical necessity criteria for Vyleesi, since the FDA label does not cover those subtypes.

The International Society for the Study of Women's Sexual Health (ISSWSH) published a process-of-care algorithm for HSDD in 2019 in Mayo Clinic Proceedings, which provides a structured diagnostic framework that maps directly onto Anthem's PA criteria. Using this algorithm in clinical documentation simultaneously serves the patient and strengthens the PA submission.

When to Involve a HealthRX Clinician

Patients who have already received a denial, or whose prescribers are not familiar with the PA submission process, benefit from involving a telehealth clinician experienced in HSDD pharmacotherapy. A clinician who can document the secondary-cause workup, write a detailed letter of medical necessity, and coordinate the appeal letter reduces the administrative burden on both the patient and the local prescriber.

A 2021 survey published in the Journal of Women's Health found that 61% of women with HSDD reported their primary care physician did not initiate a pharmacotherapy discussion, suggesting that specialist involvement often produces more complete clinical documentation from the outset.

The HealthRX HSDD intake protocol captures FSH level, menstrual cycle history, comorbid psychiatric diagnoses, current medication list (screened for libido-suppressing agents), and prior counseling history in a single visit. That information is assembled into a PA packet before the prescription is transmitted.

The Vyleesi FDA label specifies a maximum of one dose per 24-hour period, and the auto-injector should be used no more than approximately eight times per month based on clinical data. Starting with four injectors per month covers most patients' clinical needs and aligns with the quantity Anthem most commonly approves on first PA approval. Requesting more than eight injectors initially is a known trigger for additional clinical review and should be reserved for cases with documented higher frequency of sexual activity.